Visual acuity benefit seen with SnET2 photodynamic therapy
August 1st 2004Fort Lauderdale, FL-The investigational drug tin ethyl etiopurpurin (SnET2) produced a visual acuity benefit and slowed the development of neovascular lesions in two phase III trials of SnET2 photodynamic therapy (PDT) (Miravant Medical Technologies) for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration, said Edgar L. Thomas, MD, Retina-Vitreous Associates, Los Angeles.
Pseudophakic uveitc eyes at risk for traeculectomy failure
August 1st 2004Fort Lauderdale, FL-Prior pseudophakia appears to be a risk factor for trabeculectomy failure in eyes with uveitic glaucoma, said K. Sheng Lim, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Scleral flap technique simplifies glaucoma device implantation
August 1st 2004Fort Lauderdale, FL-Experience with implantation of the Ex-PRESS miniature glaucoma device (Optonol Ltd.) under a scleral flap in high-risk eyes shows that it is a simple and effective technique for controlling IOP and reduces complications encountered with subconjunctival implantation, said Trevor R. Carmichael, MD, PhD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Survey study correlates glaucoma with cardiovascular risk
August 1st 2004Fort Lauderdale, FL-Results of the OPTIME Study show that cardiovascular risk factors are significantly more prevalent among patients with primary open-angle glaucoma (POAG) compared with unaffected controls, reported Nicola Orzalesi, MD, PhD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Combination regimen may offer best topical keratitis treatment
August 1st 2004New York-Results of an in vitro susceptibility study suggest a combination regimen consisting of clarithromycin and a fourth-generation fluoroquinolone may offer the best topical treatment for keratitis due to non-tuberculous Mycobacteria, said Mahendra K. Shah, MS.
New artificial cornea offers promise for transplant patients
August 1st 2004A new artificial cornea may offer hope to patients who have a history of multiple human donor cornea rejections. AlphaCor, manufactured by Australian-based Argus Biomedical Pty Ltd. and marketed by CooperVision Surgical Inc., is a biocompatible, flexible, one-piece artificial cornea that has been designed to replace a scarred or diseased native cornea in patients for whom corneal graft using human donor tissue is unsuitable.
Hypertonic saline is a promising alternative for LASEK flap creation
August 1st 2004Rishon Le-Zion, Israel-LASEK performed by using hypertonic saline (5% NaCl) to lift the flap may be a better alternative to alcohol-assisted LASEK, according to a recent randomized prospective study. Israeli researchers presented clinical trial results of the new method.
Relative toxicity of four ophthalmic antibiotics studied
August 1st 2004Fort Lauderdale, FL-In a comparison study that has implications for wound healing in surface ablation procedures, investigators found that four commonly used topical ophthalmic antibiotics-moxifloxacin (Vigamox, Alcon), levofloxacin (Quixin, Santen), gatifloxacin (Zymar, Allergan), and ofloxacin (Ocuflox, Allergan)-all showed evidence of toxicity on human corneal epithelial cells, with moxifloxacin causing the least amount of toxicity.
Alcon gets 2nd review of potential AMD treatment
August 1st 2004Fort Worth, TX-Alcon Inc. has filed the second of three parts of its "rolling" new drug application for anecortave acetate for depot suspension (Retaane) 15 mg, an investigational treatment for patients with wet age-related macular degeneration (AMD).
PRK recommended procedure for U.S. Naval aviators
August 1st 2004San Diego-U.S. Naval aviators can benefit from PRK in terms of restoration of visual acuity to 20/20 and enhanced flight performance, said David J. Tanzer, MD, surgical director, refractive surgery center, department of ophthalmology, Naval Medical Center, San Diego.
Glaucoma expert urges a new look at screening
August 1st 2004Fort Lauderdale, FL-More aggressive glaucoma screening methods and a better understanding of disease progression as well as its incidence and prevalence among various population groups are essential to lessening the devastating impact of this disease worldwide, said Harry A. Quigley, MD, during the 2004 Friedenwald Award lecture at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.
Single-use microkeratome produces predictable flaps
July 15th 2004San Diego-The M2 single-use microkeratome with a 130-?m head (Moria, Antony, France) appears to produce predictable flap thickness without causing any significant complications during or after LASIK, according to Richard A. Norden, MD, FACS, who spoke during the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS).
Pursuit of 'perfect' vision requires search outside the box
July 15th 2004San Diego-"The pursuit of perfect vision is analogous to the pursuit for the Holy Grail. The Holy Grail is the symbol for a large and mysterious power, closely guarded, concealed, and protected. Like the Holy Grail, perfect vision is the ultimate prize, but it is elusive," Roger F. Steinert, MD, said when he delivered the Binkhorst Lecture, "The Pursuit of 'Perfect' Vision: Ophthalmology's Holy Grail?" at the American Society of Cataract and Refractive Surgery annual meeting.
Redesigned microkeratome blade produces consistent flaps
July 15th 2004San Diego-A safety and reliability study of the redesigned BD Beaver microkeratome blade (Becton, Dickinson and Co.) in LASIK indicates that the blade results in uniformly consistent flap thickness and is unlikely to cause any intraoperative complications, said Paul J. Dougherty, MD, who presented his findings at the annual meeting of the American Society of Cataract and Refractive Surgery.
Quality of vision does not depend on corneal shape
July 15th 2004San Diego-The shape of the cornea, prolate or oblate, does not seem to affect the visual acuity or the quality of visual outcomes following wavefront-guided refractive surgery. The spherical aberration seems to be the most important element, based on the results of the VISX mul- ticenter FDA trial.
Survey shows patients happy with progressive multifocal IOL
July 15th 2004San Diego-Patients with the zonal progressive multifocal IOL (Array, AMO) report implanted improved depth of field at all levels of vision, which translates into enhanced quality of life, according to Guy E. Knolle Jr., MD, who spoke at the American Society of Cataract and Refractive Surgery annual meeting.
Accommodating IOL good option for hyperopic presbyopia
July 15th 2004San Diego-Lens-based surgery with an accommodating IOL (Crystalens, eyeonics) offers advantages for treatment of aging patients with hyperopic presbyopia that make it likely to replace laser keratorefractive procedures as the procedure of choice for the management of that patient population, ex- plained D. Michael Colvard, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.